



Dear Clinical Research Site,

We are contacting you again on behalf of AstraZeneca to assess your potential interest in a *Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY, D533BC00001)*.

Brief Summary:

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

Detailed Description:

This study will consist of two treatment arms (Groups A and B).

Participants will be randomised in a 1:1 ratio to one of the two treatment groups:

- Group A: Ceralasertib plus durvalumab combination therapy Each 28-day cycle will begin with ceralasertib administered orally followed by durvalumab administered intravenously.
- Group B: Docetaxel monotherapy Each 21-day cycle will begin with the administration of docetaxel.

Actual Study Start Date: September 15, 2022

Estimated Primary Completion Date: May 22, 2025

Estimated Study Completion Date: May 22, 2025

Could you kindly let us know if your site would be interested in participating in the feasibility process for this study? This will help us keep our trackers updated and **cease contacting you if are not interested**.

If interested, please provide full contact information for potential Principal Investigator and/or any other staff member involved in this process.

Thank you.

Best regards,

Parexel Global Feasibility Team

Noelia M. Ruzzante

Clinical Feasibility Leader

Upcoming OoO: 05th to 09th June

Parexel International

Madrid, Spain

noeliamilagros.ruzzante@parexel.com

www.parexel.com